We’re excited to join industry leaders at CPHI South East Asia 2025, happening from July 16 to 18 at MITEC in Kuala Lumpur. The event spans over 15,000 square meters and will feature around 400 exhibitors. More than 8,000 professionals are expected to attend, along with 60+ seminars and forums focused on current industry trends, new technologies, and regulatory developments. It’s an excellent opportunity for networking and collaboration across the pharmaceutical supply chain.

About JYMed
 
JYMed is a leading peptide-focused pharmaceutical company specializing in research, development, manufacturing, and commercialization. We offer fully integrated CDMO services tailored to pharmaceutical, cosmetic, and veterinary clients worldwide.

Our portfolio includes a wide range of peptide APIs. Flagship products like Semaglutide and Tirzepatide have successfully completed U.S. FDA DMF filings.

Our subsidiary, Hubei JXBio, runs advanced peptide API production lines built to meet cGMP standards from both the U.S. FDA and China’s NMPA. The facility includes 10 large-scale and pilot production lines and is supported by a strong Quality Management System (QMS) and Environmental Health and Safety (EHS) protocols.

JXBio has passed GMP inspections from both the U.S. FDA and China’s NMPA. We are proud to be recognized by global pharmaceutical partners for excellence in quality, safety, and environmental compliance. 

MAIN PRODUCTS

Contact Us
For inquiries, feel free to reach out:
● Global API & Cosmetic Inquiries: +86-150-1352-9272
● API Registration & CDMO Services (U.S. & EU): +86-158-1868-2250
● Email: jymed@jymedtech.com
● Address: Floors 8 & 9, Building 1, Shenzhen Biomedical Innovation Industrial Park, 14 Jinhui Road, Kengzi Subdistrict, Pingshan District, Shenzhen, China.